Relmada Therapeutics Statistics
Share Statistics
Relmada Therapeutics has 30.17M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 30.17M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 25.28M |
| Failed to Deliver (FTD) Shares | 50.28K |
| FTD / Avg. Volume | 5.27% |
Short Selling Information
The latest short interest is 1.26M, so 4.16% of the outstanding shares have been sold short.
| Short Interest | 1.26M |
| Short % of Shares Out | 4.16% |
| Short % of Float | 4.97% |
| Short Ratio (days to cover) | 4.52 |
Valuation Ratios
The PE ratio is -1.26 and the forward PE ratio is -1.65.
| PE Ratio | -1.26 |
| Forward PE | -1.65 |
| PS Ratio | 0 |
| Forward PS | 0.4 |
| PB Ratio | 1.46 |
| P/FCF Ratio | -2.41 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Relmada Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8, with a Debt / Equity ratio of 0.
| Current Ratio | 8 |
| Quick Ratio | 8 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.16% and return on capital (ROIC) is -121.49%.
| Return on Equity (ROE) | -1.16% |
| Return on Assets (ROA) | -1.01% |
| Return on Capital (ROIC) | -121.49% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -4.94M |
| Employee Count | 20 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -87.21% in the last 52 weeks. The beta is 0.41, so Relmada Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.41 |
| 52-Week Price Change | -87.21% |
| 50-Day Moving Average | 1.97 |
| 200-Day Moving Average | 3.1 |
| Relative Strength Index (RSI) | 26.23 |
| Average Volume (20 Days) | 953.73K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -103.70M |
| Net Income | -98.79M |
| EBITDA | 4.91M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -3.28 |
Balance Sheet
The company has 4.09M in cash and 0 in debt, giving a net cash position of 4.09M.
| Cash & Cash Equivalents | 4.09M |
| Total Debt | 0 |
| Net Cash | 4.09M |
| Retained Earnings | -560.90M |
| Total Assets | 55.72M |
| Working Capital | 47.62M |
Cash Flow
In the last 12 months, operating cash flow was -51.66M and capital expenditures 0, giving a free cash flow of -51.66M.
| Operating Cash Flow | -51.66M |
| Capital Expenditures | 0 |
| Free Cash Flow | -51.66M |
| FCF Per Share | -1.72 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RLMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -745.45% |
| FCF Yield | -389.1% |
Analyst Forecast
The average price target for RLMD is $1, which is 127.3% higher than the current price. The consensus rating is "Hold".
| Price Target | $1 |
| Price Target Difference | 127.3% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Sep 30, 2019. It was a backward split with a ratio of 1:4.
| Last Split Date | Sep 30, 2019 |
| Split Type | backward |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | -20.34 |
| Piotroski F-Score | 1 |